

(51) International Patent Classification:
C07K 16/24 (2006.01)(21) International Application Number:
PCT/US2015/020383(22) International Filing Date:
13 March 2015 (13.03.2015)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
61/968,550 21 March 2014 (21.03.2014) US(71) Applicant: ELI LILLY AND COMPANY [US/US];
Lilly Corporate Center, Indianapolis, Indiana 46285 (US).(72) Inventors: DAVIES, Julian; c/o Eli Lilly and Company,
P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).
MAGRINI, Fabio; c/o Eli Lilly and Company, P. O. Box
6288, Indianapolis, Indiana 46206-6288 (US). MARTIN,
Andrea Paula; c/o Eli Lilly and Company, P. O. Box
6288, Indianapolis, Indiana 46206-6288 (US). MOZAF-
FARIAN, Neelufar; c/o Eli Lilly and Company, P. O. Box
6288, Indianapolis, Indiana 46206-6288 (US). PATEL,Chetankumar Natvarlal; c/o Eli Lilly and Company, P. O.
Box 6288, Indianapolis, Indiana 46206-6288 (US).
SCHROEDER, Oliver; c/o Eli Lilly and Company, P. O.
Box 6288, Indianapolis, Indiana 46206-6288 (US).(74) Agent: KELLEY, James J.; Eli Lilly and Company, P. O.
Box 6288, Indianapolis, Indiana 46206-6288 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: IL-21 ANTIBODIES

Fig. 1



(57) Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.



LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))*

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*